TherapeuticsMD (NASDAQ:TXMD) Posts Quarterly Earnings Results, Beats Estimates By $6.13 EPS

TherapeuticsMD (NASDAQ:TXMD) posted its quarterly earnings data on Tuesday. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($6.12) by $6.13, Zacks reports. TherapeuticsMD had a negative return on equity of 2.41% and a negative net margin of 18.83%.

TherapeuticsMD Trading Down 0.5%

Shares of NASDAQ:TXMD traded down $0.01 during mid-day trading on Tuesday, reaching $1.95. The stock had a trading volume of 14,030 shares, compared to its average volume of 59,146. The business’s 50 day moving average price is $2.14 and its 200 day moving average price is $1.96. TherapeuticsMD has a 1 year low of $0.98 and a 1 year high of $2.95. The company has a market cap of $22.56 million, a P/E ratio of -195.00 and a beta of 0.58.

Institutional Trading of TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Renaissance Technologies LLC grew its position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 171.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 96,500 shares of the company’s stock after acquiring an additional 61,000 shares during the quarter. Renaissance Technologies LLC owned about 0.83% of TherapeuticsMD worth $157,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 30.74% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded TherapeuticsMD from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Monday, April 6th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About TherapeuticsMD

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.